ADPT

Adaptive Biotechnologies Corporation operates as a commercial-stage biotechnology company that translates immune system data into clinical products and services. Headquartered in Seattle, Washington, the company was founded in 2009 and employs approximately 450 people. Adaptive specializes in immune-driven medicine through its proprietary immune medicine platform, which combines expertise in immunology, genomics, and computational biology to decode the adaptive immune system. The company's business model centers on two primary segments: Minimal Residual Disease (MRD) testing and Immune Medicine. Its flagship product, clonoSEQ, is the first and only FDA-cleared assay for detecting MRD in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia. Adaptive also develops T-Detect, a clinical diagnostic platform that uses T-cell receptor sequencing to detect disease, with initial applications in Lyme disease and COVID-19. The company maintains strategic partnerships with Genentech for therapeutic antibody discovery and with Microsoft to map the immune response to diseases. Adaptive operates CLIA-certified laboratories and generates revenue through diagnostic testing services, pharmaceutical partnerships, and research collaborations. The company's immunoSEQ platform serves researchers globally for immune repertoire sequencing. As a precision medicine player, Adaptive positions itself at the intersection of diagnostics and drug discovery, leveraging its comprehensive immune system database to advance personalized healthcare solutions.